Clinical Trials
- Brain, Spinal Cord & Nervous System
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis (CONSONANCE)
- Ages18 years - 65 years
- GenderBoth
- Date12/18/2018
- Brain, Spinal Cord & Nervous System
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS)
- Ages18 years - 55 years
- GenderBoth
- Date06/29/2016
- Brain, Spinal Cord & Nervous System
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis (ExTINGUISH)
- Ages18 years and older
- GenderBoth
- Date05/06/2022
- Brain, Spinal Cord & Nervous System
Study of Safety and of the Mechanism of BLZ945 in ALS Patients
- Ages18 years - 75 years
- GenderBoth
- Date02/28/2022
- Brain, Spinal Cord & Nervous System
Multiple Sclerosis: Symptoms and Hormones Study
- Ages18 years - 45 years
- GenderFemale only
- Date04/13/2021
- Myeloma
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
- Date02/28/2020
- COVID-19 Inpatient, COVID-19 Outpatient
Patient response to COVID19 outbreak
- Ages18 years and older
- GenderBoth
- Date05/11/2020
- Myeloma
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
- Date10/14/2019
- Brain, Spinal Cord & Nervous System
Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
- Ages18 years and older
- GenderBoth
- Date02/16/2022
- Myeloma
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
- Date02/21/2022